
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
The Cigna Group is anticipated to experience robust growth driven by its Evernorth segment, which is expected to enhance patient satisfaction, reduce costs, and improve health outcomes. The company projects a recovery in stop loss margins, contributing to Healthcare segment adjusted operating income growth at the higher end of its long-term target of 7%-10%, supported by pricing strategies and selective growth initiatives. Additionally, strong free cash flow is expected to facilitate ongoing capital deployment, allowing Cigna to broaden its service offerings and sustain core growth trends.
Bears say
The financial outlook for Cigna Group appears negative due to anticipated declines in its Evernorth Adjusted Operating Income (AOI), projected to drop from $3,506 million in CY25 to approximately $2,749 million in CY26, representing a year-over-year decrease of $758 million. This decline is attributed to PBM margin headwinds, a transition to a rebate-free model expected to reduce earnings by $500 million to $600 million, and the expectation of a reduction in AOI margins for top customers. Additional challenges include risks related to accurately pricing and managing healthcare cost trends, a slowdown in biosimilar adoption, and potential client losses within the Evernorth segment.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares